I have the report as a PDF with the chromatogram on page two, so I can quote specifics.
I suspect the usual explanation for this is wrong, or at least incomplete.
I am aware this may have a boring answer. I would still like the boring answer stated clearly.
What is actually going on here, physically?
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemIf a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
It helps to be literal here: if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
If testing multiple vials, state how many you tested and why you chose those vials.
Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 27 Aug 2024 by bufferline42 — added the placebo-arm figures
A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
edited 27 Aug 2024 by leah_ferrers — fixed an arithmetic slip in the third paragraph
It helps to be literal here: start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
If testing multiple vials, state how many you tested and why you chose those vials.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.